Public Citizen, representing more than 100,000 consumers nationwide, hereby petitlons the Food and Drug Administration (FDA) pursuant to the Federal Food, Drug and Cosmetic Act 21 U.S.C. Section 355(e)(3), and 2 1 C.F.R. 10.30, to immediately ban the third generation oral contraceptives containing desogestrel due to the approximately doubled risk of venous thrombosis (30 cases for every 100,000...

BACKGROUND Epidemiological studies have shown that both the estrogen dose and progestogen type of oral contraceptives contribute to the increased risk of thrombosis in oral contraceptive users. Thrombin generation-based activated protein C (APC) sensitivity is a global test for the net prothrombotic effect of oral contraceptives and predicts the thrombotic risk. Our objective was to test the us...

serum total fatty acids were estimated in controls and women using the oral contraceptives eugynon (containing 0.5 mg.of norgestron and 0.05 mg ethinyl oestradiol) and lyndiol (containing 2.5 mg. of linostrol and 0.05 mg of ethiny oestradiol) for periods ranging from 8 to 110 weeks. the serum total fatty acids level was found to be approximately 70% higher in the women using oral contraceptives...

BACKGROUND AND PURPOSE Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives. METHODS A multicenter, population-based, case-control study was performed in 9 Dutch cent...

Recently, a population-based case-control study observed a 60% increased odds ratio (OR) for cutaneous squamous cell carcinoma (SCC) among women who had ever used oral contraceptives (OCs) compared with non users (95% confidence interval (CI) = 1.0-2.5). To further characterize the putative association between OC use and SCC risk, we conducted a nested case-control study using a large retrospec...

BACKGROUND Two recent studies, a cohort study from Denmark, and a case-control study from The Netherlands, have reported increased risks of venous thromboembolism (VTE) among users of oral contraceptives (OCs) containing desogestrel, gestodene, drospirenone and cyproterone, relative to the use of levonorgestrel. CRITIQUE In the Danish study the comparisons were not valid. (1) VTE risk is high...

OBJECTIVE To compare the risk of non-fatal venous thromboembolism in women receiving oral contraceptives containing drospirenone with that in women receiving oral contraceptives containing levonorgestrel. DESIGN Nested case-control and cohort study. SETTING The study was based on information from PharMetrics, a United States based company that collects information on claims paid by managed ...

Menstrual disturbances are common among female athletes, and oral contraceptives (OCs) are often recommended as estrogen substitution. However, there is little information about the effects of OC use in athletes, and there is great concern that OCs might impair physical performance. The aim of this study was to investigate the effects of OC use on body composition and physical performance in fe...